Welcome to the Power of the Combination Media Workshop
This site has been developed by OncoLink as an information resource on current and critical issues affecting the treatment of cancer.
Every year 10 million new cases of cancer are diagnosed globally, only a third of which can be effectively treated. Combination therapy, however is promising to become the cornerstone for cancer treatments, offering patients improved response rates and tolerability. Phase III clinical data, to be presented at the media briefing discusses the role of Gemzar® based therapies in increasing treatment effectiveness and how they are one of the tools necessary to transform cancer from an acute to a chronic and manageable disease.
This webcast is based on information presented at the Power of the Combination Media Workshop conducted at the European Society for Medical Oncology congress in Nice, France, October 19, 2002.
In order to view this webcast, you will need Windows Media Player and Microsoft Internet Explorer or Netscape Navigator 4.X. Please see our help page for further information.
Agenda
| 10:30 | ACE Reporter Award (also see ACE Reporter Award - 2003) |
| 10:45 | Welcome Dr. Jorge Otero Medical Director of the Gemzar Product Team Eli Lilly and Company |
| 10:50 | Gemzar: The history, the progress, the future Dr. Lucio Crino Bellaria Hospital Bologna, Italy |
| 11:10 | Gemzar: Innovative Combinations for Optimal Cancer Care Dr. Christian Manegold Professor of Medicine, University of Heidelberg Thoraxklinik-Heidelberg GmbH, Germany |
| 11:30 | Question & Answer Session Chaired by Dr. Christian Manegold |
For additional news about novel cancer treatments please see these articles:
Phase III single-blinded study of premexetred + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma
Pemetrexed performs well in metastatic breast cancer trials
Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG)
Supported by an unrestricted educational grant from Eli Lilly and Company.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home